Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Huperzine A - Neuro-Hitech/Xel

Drug Profile

Huperzine A - Neuro-Hitech/Xel

Alternative Names: HupA transdermal; Qian-ceng-ta transdermal; XEL 001HG; XEL 001HP

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayo Clinic
  • Developer Guangzhou Xiangxue Pharmaceuticals; Neuro-Hitech; Xel Pharmaceuticals
  • Class Alkaloids; Neuroprotectants; Nootropics; Sesquiterpenes; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in China (Transdermal, Patch)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Topical, Gel)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Transdermal, Patch)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top